TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Incidence of arbovirus infection
Endpoint domain: Adverse events/effects
Primary endpoint: Grade 3 or above local solicited adverse event
Endpoint domain: Adverse events/effects
Primary endpoint: Grade 3 or above systemic clinical and laboratory solicited adverse event
Endpoint domain: Adverse events/effects
Primary endpoint: Any grade of adverse event that results in a clinical decision to discontinue further immunisations
Endpoint domain: Adverse events/effects
Primary endpoint: Change of working memory
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change of response inhibition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change of attention bias
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change of risk decision
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: duration of hospitalization after surgery
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Number of lymph nodes retrieved
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of participants with abnormal laboratory values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of participants with abnormal physical status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detruser pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Clinical pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Degree of nausea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: change in sedation level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time Line Follow-back
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Sensory Perception Quotient score, short form at 1 year
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Sensory Perception Quotient score, short form at 2 years
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in scapular plane abduction strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Isometric strength measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Isokinetic strength measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: COVID-19 positivity status
Endpoint domain: Mortality/survival
Primary endpoint: Cellular immunity induction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Delay discounting rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Food reinforcement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hospitalization after hip fracture surgery
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Blood Flow Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage requiring dilation and curettage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: failure to expel products of conception
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Incidence of pulmonary hypertension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rapidity of myeloid engraftment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Depression at End of Treatment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Patient Assessment of Constipation-Symptom questionnaire
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Patient Assessment of Constipation Quality of Life Questionnaire (PAC-QOL)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Investigator's Global Assessment (IGA) Success at Week 16
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Eczema Area and Severity Index (EASI-75) Improvement at Week 16
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in bone healing parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: concentration of Hemoglobin A1c
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: serum concentrations of high density lipoproteins-cholesterol (HDL-C)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Stage of apical compartment defect
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: DNA extraction of tumor tissue samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: cumulative incidence of oral mucositis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient quality of life (QOL)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Weight gain due to fat mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Clinical safety of 89Zr-ss-pertuzumab
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of patients with undetectable serum PSA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: State trait Anxiety inventory (STAI)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Maslach Burnout inventory (MBI)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Root mean square of successive differences (RMSSD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: High frequency percentage in the spectral analysis of the heart RR interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Need for post-bariatric surgery ICU admission
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Patient-reported neck and shoulder function
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Difference in forearm pressures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anatomical and functional outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Requirement of reoperation
Endpoint domain: Adverse events/effects
Primary endpoint: Subjective recurrence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Grade 3-4 Drug-related Skin Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Subjective feelings
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: graft re-injury or graft failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in 24-hour Ambulatory Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Total Scale Score for the Repeatable Battery for the Assessment of Neuropsychological Status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Onset of dementia
Endpoint domain: Mortality/survival
Primary endpoint: Number of Thoracic Spinal Segments Successfully Visualized
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Subjective Comfort Scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: ADAS-cog Change From Baseline to Week 52
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Objective measure of physical activity in MET min/week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjective measure of physical activity in MET min/week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Density rate of ICU-acquired infections
Endpoint domain: Adverse events/effects
Primary endpoint: Duodenal-biliary reflux rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in Kilocalories of Sugar-Sweetened Beverages
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mastication
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occlusal Load
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of vascular access complications and bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Immune response to Oxy(Gly)4-sklh
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Effects of Vaccine on Intranasal Drug Positive Subjective Effects
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: HPA Reactivity Profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Recurrence-free Survival Rate at 5 Years
Endpoint domain: Mortality/survival
Primary endpoint: Change in motor delay
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Genes Significantly Associated With 25OHD Blood Vitamin D Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Evaluation of thyroid cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Evaluation of thyroid disorders
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Rate of pacemaker syndrome
Endpoint domain: Adverse events/effects
Primary endpoint: Sustained Virologic Response (SVR) at 12 Weeks After Discontinuation of Therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Relief of Nasal Congestion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inpatient response to medical management
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: walking distance without pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma electrolyte levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in self-management
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Allergic Rhinitis Symptom Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful catheter insertion at first attempt
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Incidence of hematoma recurrence/progression requiring re-intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Postoperative orbital pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sepsis-related signs and symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Polisomnography analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correlation coefficient between patients profile and type of pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of miRNAs in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Detectability of miRNAs in CSF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Participants with Non-Serious Adverse Event(s)
Endpoint domain: Adverse events/effects
Primary endpoint: AUC0-24h of caffeine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: AUC0-120h of Warfarin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: AUC0-24h of Omeprazole
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: AUC0-24h of Dextromethorphan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-24h of Midazolam IV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in affective withdrawal symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Increase in negative affect
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Increase in stress reactivity
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Increased propensity to experience food craving
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Pregnancy Pearl Index
Endpoint domain: Mortality/survival
Primary endpoint: Death or persistent organ dysfunction
Endpoint domain: Mortality/survival
Primary endpoint: Biologic markers of autophagy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Functional pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physical functional
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Sensitivity and Specificity of PET/MRI PSMA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Whole body vibration quantification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urinary HFIP concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Urinary sevoflurane concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Intra-class correlation coefficients for intra-rater reliability of self-measured arm circumference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intra-class correlation coefficients for inter-rater reliability of arm circumference measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intra-class correlation coefficients for concurrent validity of self-measured arm circumference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Primary safety parameters
Endpoint domain: Adverse events/effects
Primary endpoint: Primary immunogenicity parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Plasma HIV RNA level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Eosinophil cell count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Achievement of haematological engraftment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Overall safety and tolerability (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in Visual Reading Ability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Pupil absenteeism
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Change in number of ANC visits
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of Participants With 12-Month Effectiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in thyroid hormone levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Feasibility of the single incision sub-urethral tape procedure
Endpoint domain: Surgical and medical procedures outcomes
Primary endpoint: Virtual Reality program effectiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Curve C-peptide Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Mammography Use
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: GMFR in VZV gpELISA IgG Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: GMFR in VZV ELISpot IFNg Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Health-related quality of life: SF-12
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in leg blood flow (mL/min)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in 6 min walking test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Subjects With Anti-hepatitis B (HB) Antibody Concentrations Above the Cut-off One Month After the Booster Dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Subjects With Anti-polyribosyl-ribitol-phosphate (PRP) Antibodies Concentrations Above the Cut-off One Month After the Booster Dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Subjects With Anti-diphtheria and Anti-tetanus Antibodies Concentration Above the Cut-off One Month After the Booster Dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Subjects With Anti-poliovirus Antibodies Concentration Above the Cut-off One Month After the Booster Dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Diagnosis of Lower Urinary System Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Quality of life, modified FACT-O
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Plasma levels of adiponectin, omentin-1, apelin and visfatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Urinary excretion of 8-oxoguanosine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Urinary excretion of 8-oxodeoxyguanosine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: ERK activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cost-effectiveness of nivolumab regimens
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in Maternal Macular Carotenoid Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Maternal Serum Carotenoid Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Maternal Skin Carotenoid Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ability to predict significant fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Ability to predict severe fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Ability to predict liver cirrhosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Number of Participants with Acute Dose Limiting Toxicity (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Intra- and inter-operator repeatability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic capacity of cardiac CT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Extent of Clot Lysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Hospital Mortality to Day 60
Endpoint domain: Mortality/survival
Primary endpoint: Endothelial Dysfunction (RHI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Arterial Stiffness (PWV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Volume of MRI bone marrow edema
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in MRI grading SPARCC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of pelvic pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intensity of pelvic pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes of PANSS total scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physician Global Perception of Change - Blinded Rater 1
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Physician Global Perception of Change - Blinded Rater 2
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Rating of Overall Musical Performance - Blinded Rater 1
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Rating of Overall Musical Performance - Blinded Rater 2
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Treatment-emergent Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Adverse Events Leading to Premature Discontinuation of Study Drug
Endpoint domain: Adverse events/effects
Primary endpoint: Pharmacokinetics of glimepiride
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of care process
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of Participants With Specific Graded Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Difference of temperature between tumors and adjacent tissues
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes